CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $7,959,000 | -78.2% | 564,102 | -75.8% | 0.11% | -83.4% |
| Q3 2020 | $36,491,000 | -10.6% | 2,328,698 | 0.0% | 0.67% | -16.1% |
| Q2 2020 | $40,799,000 | +41.5% | 2,328,698 | +18.7% | 0.80% | -12.7% |
| Q1 2020 | $28,830,000 | -38.7% | 1,961,209 | +4.6% | 0.91% | -36.2% |
| Q4 2019 | $47,049,000 | +66.8% | 1,875,209 | 0.0% | 1.43% | -15.1% |
| Q3 2019 | $28,203,000 | -39.8% | 1,875,209 | 0.0% | 1.68% | -33.3% |
| Q2 2019 | $46,880,000 | +9.8% | 1,875,209 | 0.0% | 2.52% | +36.8% |
| Q1 2019 | $42,680,000 | -24.1% | 1,875,209 | 0.0% | 1.84% | -43.8% |
| Q4 2018 | $56,238,000 | +15.4% | 1,875,209 | +10.2% | 3.27% | +25.6% |
| Q3 2018 | $48,734,000 | – | 1,701,017 | – | 2.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |